Prospective Assessment Project of AirwaY Management-related Incidents in Adult Anaesthesia Care PAPAYA III
Launched by INSEL GRUPPE AG, UNIVERSITY HOSPITAL BERN · Oct 30, 2023
Trial Information
Current as of July 23, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The PAPAYA III trial is a study aimed at understanding incidents related to airway management during anesthesia for adult patients. Essentially, it looks at what happens when doctors manage a patient's airway—like putting in a breathing tube or using devices that help with breathing—during surgeries or medical procedures. The goal is to analyze both major and minor problems that might occur, so healthcare providers can improve safety for future patients.
To participate in this trial, you need to be an adult over 18 years old who requires airway management for a medical procedure, whether it's planned, urgent, or emergency-related. You will need to give your consent to participate. If you join the study, researchers will collect information about your care and any incidents related to airway management that occur during your procedure. It’s important to note that the trial is not yet recruiting participants, so you won’t be able to join just yet. This study is essential for enhancing patient safety in anesthesia care, which is why your participation could help many others in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • All adult patients requiring airway management under anaesthesia care for elective, semi-elective, urgent or emergency diagnostic procedures or interventions. Airway management includes awake and asleep tracheal intubation, insertion of supraglottic airway devices, and face mask ventilation.
- • Patients older than 18 years of age
- • Informed consent given or general consent in place, according to local ethics committee requirements.
- Exclusion Criteria:
- • Refusal to give consent or withdrawal of consent.
- • Patients \<18 years.
About Insel Gruppe Ag, University Hospital Bern
Insel Gruppe AG, the umbrella organization for the University Hospital Bern, is a leading healthcare provider in Switzerland, renowned for its commitment to advancing medical research and patient care. As a key player in clinical trials, Insel Gruppe AG integrates cutting-edge scientific inquiry with clinical excellence, facilitating innovative studies that span a wide range of medical disciplines. The institution prioritizes collaboration with academic partners and industry stakeholders to enhance the understanding of diseases and develop effective treatment options, ultimately aiming to improve patient outcomes and contribute to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hamburg, , Germany
Aarau, , Switzerland
Berlin, , Germany
Lausanne, , Switzerland
Patients applied
Trial Officials
Robert Greif, MD, Prof
Study Chair
Department of Anaesthesiology and Pain Medicine, Inselspital, Bern University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported